<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4287">
  <stage>Registered</stage>
  <submitdate>25/02/2011</submitdate>
  <approvaldate>25/02/2011</approvaldate>
  <nctid>NCT01305200</nctid>
  <trial_identification>
    <studytitle>Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant</studytitle>
    <scientifictitle>A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NCI-2011-02635</secondaryid>
    <secondaryid>ACCL1031</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Childhood Acute Lymphoblastic Leukemia in Remission</healthcondition>
    <healthcondition>Childhood Acute Myeloid Leukemia in Remission</healthcondition>
    <healthcondition>Childhood Chronic Myelogenous Leukemia</healthcondition>
    <healthcondition>Childhood Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Chronic Eosinophilic Leukemia</healthcondition>
    <healthcondition>Chronic Myelomonocytic Leukemia</healthcondition>
    <healthcondition>Chronic Neutrophilic Leukemia</healthcondition>
    <healthcondition>de Novo Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Disseminated Neuroblastoma</healthcondition>
    <healthcondition>Juvenile Myelomonocytic Leukemia</healthcondition>
    <healthcondition>Mucositis</healthcondition>
    <healthcondition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</healthcondition>
    <healthcondition>Previously Treated Childhood Rhabdomyosarcoma</healthcondition>
    <healthcondition>Previously Treated Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Recurrent Childhood Acute Lymphoblastic Leukemia</healthcondition>
    <healthcondition>Recurrent Childhood Acute Myeloid Leukemia</healthcondition>
    <healthcondition>Recurrent Childhood Large Cell Lymphoma</healthcondition>
    <healthcondition>Recurrent Childhood Lymphoblastic Lymphoma</healthcondition>
    <healthcondition>Recurrent Childhood Rhabdomyosarcoma</healthcondition>
    <healthcondition>Recurrent Childhood Small Noncleaved Cell Lymphoma</healthcondition>
    <healthcondition>Recurrent Malignant Testicular Germ Cell Tumor</healthcondition>
    <healthcondition>Recurrent Wilms Tumor and Other Childhood Kidney Tumors</healthcondition>
    <healthcondition>Recurrent/Refractory Childhood Hodgkin Lymphoma</healthcondition>
    <healthcondition>Relapsing Chronic Myelogenous Leukemia</healthcondition>
    <healthcondition>Secondary Acute Myeloid Leukemia</healthcondition>
    <healthcondition>Secondary Myelodysplastic Syndromes</healthcondition>
    <healthcondition>Unspecified Childhood Solid Tumor, Protocol Specific</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Neuroendocrine tumour (NET)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Other</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Testicular</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - supersaturated calcium phosphate rinse
Other interventions - placebo
Other interventions - questionnaire administration
Treatment: surgery - quality-of-life assessment

Placebo Comparator: Arm I (placebo) - Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.

Experimental: Arm II (supersaturated calcium phosphate rinse) - Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.


Treatment: drugs: supersaturated calcium phosphate rinse
Mouth rinse

Other interventions: placebo
Mouth rinse

Other interventions: questionnaire administration
Ancillary studies

Treatment: surgery: quality-of-life assessment
Ancillary studies

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration of Severe Oral Mucositis (WHO Grade 3 or 4) - Mean days of severe (WHO Grade 3 or 4) Mucositis.</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Severe Oral Mucositis - Percentage of patients with Severe Oral Mucositis (WHO Grade 3 or 4) per arm.</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oral Mucositis Daily Questionnaire (OMDQ) - Area under the curve (AUC) of the Oral Mucositis Daily Questionnaire (OMDQ) subscales</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Parenteral Opioid Analgesic Use (Morphine Equivalents). - Opioid Administration = yes</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Parenteral Opioid Analgesic Use (Morphine Equivalents). - Mean days of parenteral opioid analgesic use.</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Dose of Parenteral Opioid Analgesic Used (Morphine Equivalents). - Morphine equivalent dose in mg/kg/day</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Total Parenteral Nutrition (TPN) Administration. - Total Parenteral Nutrition = yes</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Total Parenteral Nutrition (TPN) Administration. - Mean days of total parenteral nutrition (TPN) administration.</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Febrile Neutropenia - Fever and Neutropenia = yes</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Invasive Bacterial Infections - Invasive Bacterial Infection = yes</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of Mucositis - Area Under the Curve of Severity of Mucositis. According to mouth pain categorical rating scale ranges 0-10 with higher scores reflecting more severe pain.</outcome>
      <timepoint>Day -1 (day prior to stem cell infusion) to Day 20 following transplantation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients undergoing myeloablative autologous or allogeneic hematopoietic stem cell
             transplantation (HSCT) for any indication

          -  One or more of the following donor stem cell sources (autologous or allogeneic):

               -  Bone marrow

               -  Placental blood (umbilical cord blood)

               -  Cytokine-mobilized peripheral blood

          -  Patients eligible for allogeneic HSCT must have one of the following types of donor
             stem cells:

               -  Human leukocyte antigen (HLA)-matched sibling or parent

               -  Partially matched family donor (mismatched for a single HLA locus [Class I])

               -  Fully matched unrelated marrow or peripheral blood stem cell donor

               -  HLA-matched or partially mismatched (at least 4 of 6 match) cord blood (Class I
                  or II)

          -  Patients expecting to receive any type of myeloablative HSCT conditioning regimen are
             eligible

               -  No non-myeloablative or reduced-intensity conditioning regimens

          -  Eligible patients must not have received palifermin within 30 days prior to enrollment

          -  Eligible patients must not have received prior treatment with Caphosol</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Females of childbearing potential must have a negative pregnancy test; patients must
             agree to use an effective birth control method; lactating patients must agree not to
             nurse a child while on this trial</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Supportive Care</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>226</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,WA</recruitmentstate>
    <hospital>Royal Childrens Hospital - Herston</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>6008 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized phase III trial is studying how well Caphosol rinse works in preventing
      mucositis in young patients undergoing autologous or donor stem cell transplant.
      Supersaturated calcium phosphate (Caphosol) rinse may be able to prevent mucositis, or mouth
      sores, in patients undergoing stem cell transplant.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01305200</trialwebsite>
    <publication>Treister N, Nieder M, Baggott C, Olson E, Chen L, Dang H, Krailo M, August A, Sung L. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer. 2017 Jan 3;116(1):21-27. doi: 10.1038/bjc.2016.380. Epub 2016 Nov 22.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nathaniel Treister, MD</name>
      <address>Children's Oncology Group</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>